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Chondrosarcoma is the second most frequent 
malignant primary bone tumor in human. Orthopedic 
oncologists believe that chondrosarcoma is one of the 
most difficult types of cancer to diagnose and treat-
ment; it is also highly resistant to ionizing radiation 
action and chemotherapy. In experimental musculo-
skeletal oncology animal models are routinely used to 
assess the efficacy of new and innovative treatment 
methodologies for these tumors [1–3]. 
Quite a few animal models of chondrosarcoma have 
been developed and described in literature, such as (i) 
inoculation chondrosarcoma cell line (MCS-1) [4–5], 
(ii) allograft tumor tissue fragments on rats [6], (iii) 
human tumor xenograft implanted cell line into the 
nude mice [7–8]. In 1960’s allograft chondrosarcoma 
models were developed based on rat tumor implanta-
tion [9]. The chondrosarcoma model was established 
with repeated transplantation. However, these models 
could not show the human tumor behavior. Therefore, 
the development of a reliable animal model for chon-
drosarcoma would be a helpful tool to study tumor 
growth and progression.
To have a more similar experimental human tumor, 
human chondrosarcoma development on animal 
cases is needed. Yet, such a tumor may not be entirely 
representative of spontaneously developing chondro-
sarcoma [10]. Since animal model of human xenograft 
would be feasible and reproducible. We conducted 
this study to develop a chondrosarcoma model on 
Sprague-Dawley rat by fresh human chondrosarcoma 
tissue fragments.
Animals. Fourteen, four-week-old male Sprague-
Dawley rats (weighing 90±5 g) were taken from Razi 
Vaccine and Serum Research Institute of Iran, kept in 
separated cages at 21–23 °C, humidity 50% and 12 h light-
dark cycle. They had free access to rat chow and water. 
Animals were equally divided in xenograft-implanted and 
control groups. The implanted group received tumoral 
fresh tissue fragments. The human chondrosarcoma tis-
sue was obtained from a 37 year-old female diagnosed 
with left leg chondrosarcoma (Tumor bank number 328, 
File number 822585, Cancer Institute, Emam Khomeini 
Hospital, Tehran, Iran). The fresh sample had atypical 
and anaplastic cells as a low-grade type of tumor. All 
experimental procedures were in accordance with the 
guidelines of the animal and human ethical committee of 
Tehran university of Medical Sciences.
Surgical procedure. Animals were anesthetized 
by a mixture of ketamine (60 mg/kg i.p) and xylazine 
(10 mg/kg i.p). First the lateral skin of the right femur 
distal 1/3 was incised 5 mm and then drilled 3 mm on 
the bone. Fresh chondrosarcoma tumoral segments 
were taken from operation room, immersed in normal 
saline immediately. The segments were divided into 
very small fragments less than 0.5 mm and inoculated 
with gage 14 needle into femoral intramedullary space 
[11]. The control group was injected normal saline.
Cyclosporine A (10 mg/kg i.p) has been given for 4 
weeks from implantation day (day 0) to suppress graft 
versus host reactions [12]. Animals were weighted 
once a week throughout the experiment.
Radiological study. Post operative AP X-rays were 
taken every week for one month to assess the implan-
tation site. X-rays were obtained monthly for three 
months after immunosuppressive discontinuation. 
Histopathological study. Four weeks after the 
operation, four rats were sacrificed of each group 
to harvest their femur bones and tumoral samples 
immediately fixed in a 10% formalin solution for 24 h 
and then put in a nitric acid solution (10%) for five days 
to decalcify bone mass. Samples were embedded in 
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paraffin and sliced into 5 μm serial sections for stain-
ing Hematoxylin and Eosin (H & E). For the pathologic 
classification of chondrosarcoma, cellularity, nuclear 
format cells and necrosis were examined.
Statistical analysis. Nonparametric fisher exact test 
was used to compare between two groups (p < 0.05).
The radiological image showed sclerotic area on 
the implanted group (Fig. 1 a). The cortical bone 
presents signs of invasion and thickening of the 
periosteum. A low-grade chondrosarcoma showed 
by disruption of trabeculae, intralesional calcification 
and periosteal reaction. Around the implantation area 
was seen more opacity compared to control group 
(Fig. 1 b, c). 
a b c
Fig. 1. Radiographies after chondrosarcoma tissue fragments 
implantation: a, period of the immunosuppressive treatment 
with abnormalities and bone resorption in implanted group; b, 
immunosuppressive agent discontinue showing bone formation 
improvement; c, control group
Typical signs of chondrosarcoma were observed 
four weeks after operation implanted group (Fig. 2 a, 
c, d). Sections from tumoral areas reveal cartilage form-
ing hypercellular neoplastic tissue with lobular pattern 
of growth and foci of adjacent tissue invasion. Invasion 
occurred in bone trabeculas and bone marrow tissue as 
well as cellular criteria of chondrosarcoma (see  Fig. 2 
c, d). Section from implanted area of femur in control 
group showed normal pattern of tissue (Fig. 2 b). 
In the present study, xenograft chondrosarcoma 
induction was established in rat femoral bone by fresh 
human chondrosarcoma fragments. 
Poor prognosis of chondrosarcoma demands new 
therapeutic options to improve the overall rate of sur-
vival, especially in high-risk groups. Animal models of 
accurately reproduced human pathology, physiology 
and histology are needed to experience a new thera-
peutic strategy. Accordingly, animal xenograft cell line 
inoculation was done in nude mice, rats and hamsters 
during the last century [4–5, 13–15]. It will be more use-
ful to have animal tumoral models behave very similar to 
the human cancerous cells with minimal manipulation. 
A number of xenograft implantable human tumors 
including chondrosarcoma were prepared by treat-
ing the animals with radiation and cortisone. With the 
advent of athymic nude mice, animal immunosuppres-
sant free cancerous cell models were adopted xeno-
graft implantation [16]. In 1990’s, chondrosarcoma 
cells of human were implanted in nude mice. Since, 
this technique has become popular, so that, most of 
chondrosarcoma models used during the last two 
decades involve human chondrosarcoma tissue or cell 
lines as ectopically implanted (within subcutaneous 
tissue) in various strains of immunocompromised mice 
[10]. However, transgenic mouse chondrosarcoma 
have been observed with unpredictability of tumor 
location, multiple tumors forming and varying pheno-
types that makes this approach difficult to control as 
a function assessment model [10, 12].
a b
c d
Fig. 2. Chondrosarcoma implantations after 28 days stain with 
hematoxylin and eosin: a — bone infiltration was seen obviously, 
40X; b — control group, 40X; c, d — hyper cellularity, bone mar-
row and trabeculae infiltration in implanted group, 100X
In present study, radiographic findings show more 
opacity at the implantation region (Fig. 1 a) compared 
to control group (Fig. 1 c). Implanted region lag growth 
may result immunosuppressive agent discontinuation 
(Fig. 1 b, see Fig. 2 a, c, d). Cellular criteria of chon-
drosarcoma include lacunar spaces with more than 
one nucleus, atypical hyperchromatic nuclei and bone 
infiltration [10]. Note that penetration into the bone, 
hypercellularity and irregularity are characteristics of 
chondrosarcoma tumor. This investigation showed 
chondroid cell infiltration into the bone marrow and 
trabeculae (see Fig. 2 a), also irregularity and hyper-
cellularity were seen in histopathological images of 
treated group (see Fig. 2 c, d).
In our study it seems the ectopic chondroid cells at 
the intramedullary bone region may be related to well-
differentiated chondroid cells or benign tumor in focal 
site. Thus, the present study shows that animal xenograft 
chondrosarcoma can be produced from fresh human 
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fragments. The advantages of this kind of method are 
reproducibility, feasibility and cost effectiveness. Based 
on, chondrosarcoma xenograft can be a helpful model 
in human cancer studies and may be a good adjuvant 
to assess the efficacy of new and innovative treatment 
methodologies for chondrosarcoma tumors.
CONCLUSION
The present study showed that xenograft chondro-
sarcoma in rat can be developed by human chondro-
sarcoma tissue fragments.
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